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Genotype-imputation methods provide an essential technique for high-resolution genome-wide association (GWA) studies with
millions of single-nucleotide polymorphisms. For optimal design and interpretation of imputation-based GWA studies, it is important
to understand the connection between imputation error and power to detect associations at imputed markers. Here, using a 2 3 3 chi-
square test, we describe a relationship between genotype-imputation error rates and the sample-size inﬂation required for achieving
statistical power at an imputedmarker equal to that obtained if genotypes at the marker were knownwith certainty. Surprisingly, typical
imputation error rates (~2%–6%) lead to a large increase in the required sample size (~10%–60%), and in some African populations
whose genotypes are particularly difﬁcult to impute, the required sample-size increase is as high as ~30%–150%. In most populations,
each 1% increase in imputation error leads to an increase of ~5%–13% in the sample size required for maintaining power. These results
imply that in GWA sample-size calculations investigators will need to account for a potentially considerable loss of power from even low
levels of imputation error and that development of additional genomic resources that decrease imputation error will translate into
substantial reduction in the sample sizes needed for imputation-based detection of the variants that underlie complex human diseases.The genotype-imputation strategy for case-control genetic
association studies provides an economical way of assess-
ing many more genetic markers for disease association
than have actually been measured in any particular associ-
ation study.1–5 In this approach, case and control individ-
uals are ﬁrst genotyped for markers densely spread across
the human genome. The measured genotypes are then
combined with high-resolution genotypic data from
genomic databases for imputation of the genotypic status
of study individuals at markers investigated in the database
but not in the study sample. This imputation relies on the
principle that two haplotypes identical in genotype at
nearby SNP markers are likely to share intervening chro-
mosomal stretches identically by descent. Thus, if a haplo-
type in a densely genotyped database sample is identical to
a haplotype in a more sparsely genotyped study sample for
markers that overlap between the study and the database,
then one can impute the study haplotype with high reso-
lution by copying the haplotype from the database.
Methods relying on genotype imputation have proven
effective for identifying high-risk disease-associated
genetic variants, in part because they dramatically increase
the number of markers that can be directly tested for asso-
ciation in comparison to earlier tag-SNP designs.6–10
However, the imputation strategy utilizes in its association
tests estimated genotypes that are not known with
certainty, and errors in imputed genotypes might poten-
tially compromise the power of an imputation-based asso-
ciation test. For example, at a biallelic marker, consider a
disease-susceptibility allele of small effect that has a true
frequency of 0.3 in cases and 0.2 in controls. If the proba-
bility that imputation recovers the true allele is 0.9, then692 The American Journal of Human Genetics 85, 692–698, Novemthe frequency of the disease allele among imputed geno-
types will be (0.3)(0.9) þ (0.7)(0.1) ¼ 0.34 in cases and
(0.2)(0.9) þ (0.8)(0.1) ¼ 0.26 in controls. Imputation error
converts an allele-frequency difference of 0.3  0.2 ¼ 0.1
between cases and controls into a smaller difference of
0.34  0.26 ¼ 0.08. As a result, for the imputed genotypes,
one might require a larger sample size in order to deter-
mine that allele frequencies differ between cases and
controls, as compared to the smaller sample size that
would be required if the true genotypes were known.
Although recent studieshave found that imputationerror
rates are generally low,11–15 it is possible that even low error
rates could have considerable effects on downstream anal-
yses. How does the error inherent in genotype imputation
reduce the power of an association study when alleles at
the true disease SNP are imputed rather than known? An
answer to this question is important to the design and inter-
pretation of imputation-based association studies. Relating
imputation error and power would assist investigators in
calculating sample sizes required for detecting disease
variants at loci whose genotypes are imputed, as well as in
determining whether imputation studies in particular pop-
ulations are likely to be underpowered. Additionally, a rela-
tionship between imputation error and power would aid in
the development of resources for genomic studies. For
example, use of such a relationship could assist in the iden-
tiﬁcation of populations in whom existing resources
producehigh error rates that limit the potential for practical
mapping of risk variants with imputation strategies.
The problem of connecting imputation error to power is
similar to a corresponding problem in the context of tag
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as a result of imputation error at a disease-susceptibility
locus can obscure the association between the locus and
disease. In the tag-SNP context, the loss of information
as a result of using a tag SNP rather than the true disease
SNP has an analogous effect. In both situations, missing
information about the correct genotypes at the true
disease-susceptibility locus contributes to a loss of power
for detecting disease association.
For the tag-SNP context, consider two loci, a SNP caus-
ally associated with disease and a nearby tag SNP. If the
r2 correlation statistic for linkage disequilibrium (LD)
between the tag SNP and the disease SNP is equal to c,
then a chi-square test statistic for disease association at
the true disease SNP in a case-control sample of total size
N has approximately the same asymptotic distribution
under the alternative hypothesis of disease association as
the corresponding chi-square statistic at the tag SNP in
a case-control sample of size N/c.16 Thus, the ‘‘sample-
size inﬂation factor’’ required in using the tag SNP in an
association study rather than the true disease SNP is ~1/c.
Motivated by this result, investigators have proposed
multiple versions of an r2 correlation statistic between the
imputed genotypes at a SNP and the true genotypes.17–19
Such statistics, which are sometimes used for identifying
markers imputed with high accuracy in imputation-based
genome-wide association (GWA) studies,6,20 have been
viewed as conceptually analogous to the r2 statistic for LD
between a tag-SNP and a disease SNP, but they have not
been shown to be mathematically equivalent to it. In the
imputation context for a biallelic SNP with alleles A and
B, the correlation between true and imputed genotypes is
a function of a 3 3 3 table, in which each of three possible
true genotypes (AA, AB, BB) has one of three possible impu-
tations. In the tag-SNP context, however, if the disease SNP
has allelesA and B and the tag SNP has allelesC andD, then
the corresponding table is a 2 3 2 table, containing entries
for the counts of the four possible haplotypes (AC, AD, BC,
BD). Although the close analogy between the tag SNP and
imputation contexts suggests that the relationship between
imputation error and power is similar to that observed
between power and LD with a tag SNP, at present the
connection between imputation r2 statistics and power
remains informal.
Here, in order to investigate the mathematical relation-
ship between imputation error and power, we adapt a
method developed for evaluating the relationship between
genotyping error and power.21,22 Our approach does not use
an r2 statistic, and unlike the inﬂation factor in the tag-SNP
context, which depends only on the LD between the tag
and disease SNPs, the corresponding inﬂation factor in
the imputation context is a function of nine parameters.
Consider two 2 3 3 chi-square tests of association, exam-
ining the relationship between the three possible geno-
types of a biallelic marker and case-control status. The ﬁrst
test uses the true genotypes of the marker, whereas the
second test uses genotypes measured with the possibility
of imputation error. Suppose that k is the ratio of theThe Americannumber of controls to the number of cases. Denote by
MAFcontrols the frequency of the minor allele in controls,
and by MAFcases the frequency of this same allele in cases.
Thus, 0 % MAFcontrols % 1/2 and 0 % MAFcases % 1. We
label the minor allele in controls by A, the major allele
in controls by B, genotype AA by 1, AB by 2, and BB
by 3. For i, j ˛ {1, 2, 3}, we let 3ij be the probability
that genotype i is imputed as genotype j. Because
P3
j¼1 3ij ¼ 1 for each i, only six error parameters must be
considered: 312, 313, 321, 323, 331, and 332.
Gordon et al.21 and Kang et al.22 determined the rela-
tionship between the two 2 3 3 chi-square test statistics
at a locus, showing that the test statistic for association
between true genotype and disease in a sample of size N
has the same asymptotic distribution as the test statistic
for association between imputed genotype and disease in
a sample of size Nf, in which f R 1 is a rational function
of 312, 313, 321, 323, 331, 332, k, MAFcases, and MAFcontrols
that represents the sample-size inﬂation factor. Thus, if
a sample size of at least N is required for achieving a speci-
ﬁed level of power when genotype is measured without
error, then a sample size of at least Nf is required for
achieving the same power when genotype is imputed
with error. We use a special case of the formula for f,
assuming k ¼ 1, so that a study has an equal number of
cases and controls. We also assume that Hardy-Weinberg
proportions are satisﬁed separately in cases and controls.
With these assumptions, the sample-size inﬂation factor
due to imputation error can be written as f ¼ g/g*, deﬁning
g and g* as in equations 1 and A.1 of Kang et al.22 and
matching our notation to that of Kang et al., with the
substitutions P01 ¼MAF2cases, P02 ¼ 2MAFcases(1 MAFcases),
P03 ¼ (1  MAFcases)2, P11 ¼ MAF2controls, P12 ¼ 2MAFcontrols
(1  MAFcontrols), and P13 ¼ (1  MAFcontrols)2.
To evaluate the sample-size inﬂation factor f at levels of
imputation error appropriate for typical association
studies, we ﬁrst estimated the six error parameters by using
genotypes of 426 individuals in 29 diverse populations.
Employing reference panels of phased haplotypes based
on ~2,000,000 SNPs in 210 HapMap Phase II individuals
together with ~500,000 SNPs from a worldwide study,23
we imputed individual genotypes at markers that were
included in the reference data but not in the worldwide
study. For each population, we repeated the imputations
underlying Figure 7 of Huang et al.,19 using the same proce-
dure that was used by Huang et al.,19 to obtain an imputed
data set of 513 markers. This set consisted of probabilistic
imputations relying on the subset of reference individuals
that, among seven choices in the work of Huang et al.,19
produced the highest imputation accuracy for that popula-
tion. The genotypes of Pemberton et al.,24 which update
those reported by Conrad et al.,25 were treated as true geno-
types of the 513 markers for measurement of 3ij. For each
population, at each marker, the minor and major alleles
were determined only with the use of the ‘‘true’’ genotype
data from that population. If each allele had a frequency of
50%, then the minor allele was assigned at random.Journal of Human Genetics 85, 692–698, November 13, 2009 693
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Figure 1. Genotype Misclassification Rates at Imputed Loci, in Each of 29 Populations
Each bar plot presents a particular error rate 3ij, in which 3ij represents the probability that genotype i is imputed as genotype j (1, minor
allele homozygote; 2, heterozygote; 3, major allele homozygote). For each population, the greatest of the six error rates is shown in
a color characteristic of the geographic region of the population. For convenience in interpreting the ﬁgure, the vertical dashed line indi-
cates 15% error. The values plotted in the ﬁgure appear together with the overall imputation error rate in Table S1.Treating the 426 individuals as unaffected, we classiﬁed
218,345 true genotypes (426 3 513, excluding missing
data) by category, and for each population, we estimated
312, 313, 321, 323, 331, and 332. Each true genotype was cate-
gorized as follows: 1, minor allele homozygote; 2, hetero-
zygote; 3, major allele homozygote. Considering all true
genotypes in a population at all 513 markers, denote the
number of true genotypes of types 1, 2, and 3 by n1, n2,
and n3, respectively. For each population, n1, the smallest
of the three quantities, was at least 70, so that at least 70
true genotypes were used in estimating each error param-
eter. For n1, n2, and n3, the medians across populations
were 411, 1967, and 3679, respectively.
To incorporate the uncertainty inherent in imputing
a genotype, we obtained posterior probabilities of
imputing types 1, 2, and 3. Considering the ni geno-
types of type i, denote the posterior probability that
genotype [ was imputed to have type j by qij[. For
each i, j ˛ {1, 2, 3}, i s j, we computed 3ij for the pop-
ulation as
Pni
[¼1 qij[=ni. The ‘‘overall imputation error
rate,’’ a weighted average of the 3ij that evaluates the
total fraction of alleles imputed incorrectly, was calcu-694 The American Journal of Human Genetics 85, 692–698, Novemlated as ½ð312=2þ 313Þn1 þ ð321=2þ 323=2Þn2 þ ð331þ
332=2Þn3=ðn1 þ n2 þ n3Þ.
For each population, Figure 1 displays the estimated
values of 3ij. In most populations, the highest imputation
error rate is 312, indicating that, conditional on true geno-
type, the highest-probability error is misclassiﬁcation of
a minor allele homozygote as a heterozygote. The next
highest error rate is usually 313 or 323, reﬂecting misclassiﬁ-
cation probabilities for minor allele homozygotes or
heterozygotes, respectively, as major allele homozygotes.
Misclassiﬁcation probabilities for major allele homozy-
gotes or heterozygotes as minor allele homozygotes (331
and 321, respectively) are generally low.
Treating the estimated values of 3ij as parametric values,
for each population, we evaluated the sample-size inﬂation
factor f for various choices of the unknown MAFcases and
MAFcontrols. Because the difference d¼MAFcasesMAFcontrols
can be viewed as a measure of the magnitude of the associ-
ation at a disease locus, we reparametrized f in terms of
d andMAFcontrols. Thus, using observed levels of imputation
error, we examined the properties of f across the range of
possible frequencies for the disease allele in cases andber 13, 2009
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Figure 2. Sample-Size Inflation Factor f Required for Maintaining Statistical Power at Imputed Loci, as a Function of the True Differ-
ence in the Frequency of the Minor Allele between Cases and Controls
Each plot utilizes the estimated imputation error rates in Figure 1 for a speciﬁc population. For each population, the inﬂation factor is
plotted for ﬁve choices of the true minor allele frequency in controls (0.05, 0.15, 0.25, 0.35, and 0.45). Note that MAFcontrols ranges from
0 to 0.5, whereas MAFcases, representing the frequency in cases of the minor allele in controls, ranges from 0 to 1. We used a step size of
0.001 for MAFcases and disregarded points with MAFcases ¼ MAFcontrols.controls (Figure 2). For most choices of the parameter
values in most populations, the inﬂation factor f lies
between 1.1 and 1.6. For most African populations, consis-
tent with their higher imputation error rates, f is consider-
ably greater than in other populations, ranging from 1.3 to
2.5 for most choices of the parameter values. The inﬂation
factor is especially high in the San and Mbuti Pygmy pop-
ulations, in which nearly all choices examined for d and
MAFcontrols produce f T 1.7. Disease alleles are difﬁcult to
detect when jdj is small, and Figure 2 demonstrates that
for several populations, the sample-size inﬂation factor is
greatest for small jdj, particularly when the disease locus
has a low minor allele frequency of MAFcontrols ¼ 0.05.The AmericanBecause the parameters MAFcases and MAFcontrols are
unknown in actual association studies, for each popula-
tion, conditional on the imputation error parameters 3ij,
we examined the minimal and maximal values of the
sample-size inﬂation factor f across the range of possible
values for MAFcases and MAFcontrols (Figure 3). For most
non-African populations, across most of the range of
possible values for the minor allele frequency in controls,
the minimal f is typically in the range of 1.1–1.2 and the
maximum is typically in the range of 1.2–1.6, indicating
that the extra sample size required for maintaining power
is usually at least 10%–20% and at most 20%–60%. The
maximal f is generally greater for low values of MAFcontrols.Journal of Human Genetics 85, 692–698, November 13, 2009 695
Upon examining the minimal and maximal sample-size
inﬂation factor across the range of disease allele frequen-
cies (Figure 3), we observe that the values are greatest in
populations with the highest imputation error rates
(Figure 1). Figure 4 quantiﬁes this observation, illustrating
the relationships with overall imputation error rate of the
minimal and maximal values of f. A linear regression of
the minimal sample-size inﬂation factor on overall impu-
tation error rate when MAFcontrols is ﬁxed at 0.3, forced
through the point at which no imputation errors occur
and therefore no sample-size inﬂation occurs, provides
a close ﬁt for most populations, with the exceptions of
the San and Mbuti Pygmy populations. The slope for this
regression is 6.911, and the corresponding regression for
the maximal sample-size inﬂation factor has a slope of
10.177. Excluding the San and Mbuti Pygmy populations,
the slopes of the regressions for the minimal and maximal
sample-size inﬂation factors decrease to 6.203 and 8.836,
respectively (Figure S1, available online). The regression
slopes generally lie between 5 and 13 when MAFcontrols is
ﬁxed at various values across its range, with the San and
Mbuti Pygmy populations either included or excluded
(Figures S1 and S2). These values have the interpretation
that each 1% increase in overall imputation error rate
translates to an increase of ~5%–13% in the sample size
required for maintaining power.
Our results have important implications for imputation
studies. In the tag-SNP setting, for small values of x, a high
LD level of r2 ¼ 1  x produces a relatively small sample-
size inﬂation factor of 1/(1  x) z1 þ x, so that each 1%
loss in the r2 measure of LD leads to a ~1% gain in the
required sample size. In the imputation setting, however,
imputation accuracy of 1  x produces a typical inﬂation
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Size Inflation Factors at Imputed Loci as
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Frequency in Controls, in Each of 29 Popu-
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For each value of MAFcontrols from 0.005
to 0.5 with a step size of 0.005, the value
plotted is the maximal or minimal value
of the inﬂation factor f obtained across
choices of MAFcases ranging from 0 to 1
with a step size of 0.001 (MAFcases s
MAFcontrols). Graphs for individual popula-
tions are color-coded by geographic region.
(A) Maximal sample-size inﬂation factor.
(B) Minimal sample-size inﬂation factor.
factor of ~1 þ 5x to ~1 þ 13x, so that
each 1% loss in imputation accuracy
leads to a ~5%–13% increase in the
required sample size. As a result, even
low levels of imputation error
can have sizeable consequences. For
example, measures that aim to assess
genomic coverage for imputation
methods might need to require strin-
gent levels of imputation error in evaluating the proportion
of the genome that is suited to imputation-based associa-
tion mapping. Studies that aim to conﬁrm associations at
imputed markers in populations with lower imputation
accuracy might inherently be disadvantaged for success in
replication studies. In these various settings, careful assess-
ment of appropriate sample sizes in power calculations will
be essential for progress in imputation-based disease-gene
identiﬁcation.One key observation is that imputation error
produces the greatest sample-size inﬂation formarkers with
lowminor allele frequency (MAFcontrols% 0.1), and for such
markers, the sample-size inﬂation for each 1% imputation
error can be as high as ~15%–35% (Figures S1 and S2). As
GWA efforts begin to focus on the impact of rare alleles on
complex diseases, the potentially serious effects of imputa-
tion error for detecting such alleles will be a central consid-
eration for forthcoming studies. For such studies, it will be
informative to examine values of the imputation error
parameters 3ij evaluated speciﬁcally from rare alleles.
We note that the linear dependence of the minimal and
maximal sample-size inﬂation factor on overall imputation
error rate, as illustrated in Figure 4, is only approximate.
This approximate linear relationship arises because the
overall imputation error rate is a composite parameter
dependent on the six underlying 3ij parameters, each of
which affects the inﬂation factor in an approximately
linear manner. On the basis of a ﬁrst-order Taylor series
expansion for f, for each i and j, Kang et al.22 derived cost
functions Cij, so that if all error parameters except 3ij are set
to zero and 3ij is small, then the sample-size inﬂation factor
is approximately 1 þ Cij3ij. These linear approximations
accurately reﬂect the sample-size inﬂation factor in most
populations except at the lowest values of MAFcases and696 The American Journal of Human Genetics 85, 692–698, November 13, 2009
MAFcontrols (results not shown) and suggest that in general,
the greatest cost is incurred from errors in imputing minor
allele homozygotes as major allele homozygotes (Figure 5).
It is noteworthy that the linear regressions in Figure 4
provide the poorest underestimates in the San population,
for which the parameter 313 for the most costly type of
error is high and for which the pattern of errors differs
somewhat from the corresponding patterns in the other
populations (Figure 1).
Although an increased sample size provides one
approach to maintaining power in an imputation-based
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Figure 4. Maximal andMinimal Sample-Size Inflation Factors as
Functions of the Overall Imputation Error Rate, for an Imputed
Disease Locus with a True Minor Allele Frequency of 0.3 in
Controls
Populations are color-coded by geographic region, and two data
points appear for each population: a maximum and a minimum.
Best-ﬁt linear-regression lines for the maxima and minima, forced
through the point (0,1), indicate the increase in the inﬂation
factor with increasing imputation error rate. For example, the lines
indicate that in most populations, at MAFcontrols ¼ 0.3, imputation
error rates of 2%–6% correspond to sample-size inﬂation factors of
~14%–53%, and each additional 1% increase in imputation error
corresponds to a ~7%–10% increase in the inﬂation factor.The Americanstudy, an alternative strategy is to decrease imputation
error instead. Reductions in imputation error can be
achieved through a combination of algorithmic advances
and optimal choices of imputation algorithms,13,15
improvements in usage of existing reference panels,19,26
and expanded marker density and sample inclusion in
these panels.18,27 A fourth approach involves incorpo-
rating information on relatives of study subjects for the
improvement of phase estimates at measured markers.
Although this approach will not eliminate errors owing
to incorrect imputation conditional on correctly estimated
phase, it will reduce imputation errors that arise from
incorrect phase estimation.
For populations with relatively little imputation error in
which large samples are easily obtained, the required
sample-size increase produced by imputation error might
not pose a signiﬁcant obstacle for GWA studies. In other
populations in which subject recruitment is difﬁcult and
the sample-size inﬂation required for maintaining power
is extreme, reduction of imputation error might be more
feasible than an increase in sample size. As GWA studies
begin diversifying to incorporate additional populations
beyond the populations of European origin that have
been typical of most investigations to date,28 it will be
important to evaluate the relative merits of the various
approaches for overcoming the consequences of imputa-
tion error to improve the potential of imputation-based
association studies.
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Figure 5. Cost Coefficients as Functions of MAFcases for the Fixed
Value MAFcontrols ¼ 0.3
The coefﬁcient Cij provides an approximation for the relative
magnitude of the sample-size inﬂation that is due to the error
parameter 3ij. Thus, a small increase of x in the imputation error
parameter 3ij adds approximately Cijx to the sample-size inﬂation
factor. The sum of the six cost coefﬁcients, Csum, has the interpre-
tation that Csumx is added to the sample-size inﬂation factor when
all six of the 3ij are simultaneously set to x. Each of the cost coefﬁ-
cients was evaluated for values of MAFcases from 0.005 to 0.995 at
intervals of 0.01.Journal of Human Genetics 85, 692–698, November 13, 2009 697
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